WASHINGTON D.C. – The Trump administration has initiated a significant policy shift aimed at fast-tracking the research, approval, and accessibility of novel mental health treatments, including psychedelic therapies such as ibogaine. This move comes under a new executive order, as announced by Secretary Kennedy, who stated on social media, > "Thanks to the leadership of President Trump, under this historic Executive Order, @HHSGov will accelerate research, approval, and access to new mental health treatments, including psychedelic therapies such as ibogaine."
The executive order instructs the U.S. Food and Drug Administration (FDA) to expedite the review process for promising psychedelic drugs. FDA Commissioner Marty Makary indicated that the agency would issue National Priority Vouchers for certain psychedelics, potentially shortening the approval timeline from years to weeks for drugs aligned with national priorities. This initiative is particularly aimed at addressing serious mental illnesses, with a strong focus on supporting veterans.
Ibogaine, a naturally occurring psychoactive substance derived from a shrub, is currently classified as a Schedule I substance in the United States, indicating no accepted medical use and a high potential for abuse. Despite this, international research and anecdotal evidence suggest its potential in treating various mental health conditions, including addiction and PTSD. The order seeks to overcome these regulatory hurdles by directing the Attorney General to review products for rescheduling upon successful completion of Phase 3 clinical trials and FDA approval.
The Department of Health and Human Services (HHS) is tasked with allocating substantial funding, with reports indicating a $50 million investment through the Advanced Research Projects for Health (ARPA-H) program. This funding is intended to match state government investments to advance psychedelic research for populations struggling with serious mental illness. HHS and FDA will also collaborate with the Department of Veterans Affairs and the private sector to boost clinical trial participation and evidence generation for these experimental therapies.
President Trump emphasized the administration's commitment to finding solutions for complex and treatment-resistant conditions, stating the order offers a chance for individuals with debilitating symptoms to "reclaim their lives." The administration's focus on psychedelic treatments represents a departure from previous approaches, aiming to leverage potential breakthroughs in mental health care.
